Dr. Jessica Altman, MD
Claim this profileNorthwestern University
Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
11 reported clinical trials
26 drugs studied
Area of expertise
1Acute Myelogenous Leukemia
FLT3 positive
MLL PTD positive
HOXA10 positive
2Acute Myeloid Leukemia
FLT3 positive
MLL PTD positive
HOXA10 positive
Affiliated Hospitals
Clinical Trials Jessica Altman, MD is currently running
Venetoclax + HMA
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.
Recruiting1 award Phase 27 criteria
Screening Tool
for Myeloid Cancer
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).
Recruiting0 awards Phase 21 criteria
More about Jessica Altman, MD
Clinical Trial Related1 year of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Jessica Altman, MD has experience with
- Azacitidine
- Venetoclax
- Gilteritinib
- Cytarabine
- Nintedanib
- CC-90009
Breakdown of trials Jessica Altman, MD has run
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Relapse
Fibroblast Growth Factor Basic Form Measurement
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jessica Altman, MD specialize in?
Jessica Altman, MD focuses on Acute Myelogenous Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved FLT3 positive patients, or patients who are MLL PTD positive.
Is Jessica Altman, MD currently recruiting for clinical trials?
Yes, Jessica Altman, MD is currently recruiting for 3 clinical trials in Evanston Illinois. If you're interested in participating, you should apply.
Are there any treatments that Jessica Altman, MD has studied deeply?
Yes, Jessica Altman, MD has studied treatments such as Azacitidine, Venetoclax, Gilteritinib.
What is the best way to schedule an appointment with Jessica Altman, MD?
Apply for one of the trials that Jessica Altman, MD is conducting.
What is the office address of Jessica Altman, MD?
The office of Jessica Altman, MD is located at: Northwestern University, Evanston, Illinois 60208 United States. This is the address for their practice at the Northwestern University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.